Ascentage Pharma Group International has made significant strides in expanding patient access to its innovative cancer therapies. The company announced that both Lisaftoclax and Olverembatinib will be included in China’s 2026 National Reimbursement Drug List (NRDL). This development is crucial as it not only enhances the accessibility of these treatments for patients but also strengthens Ascentage's position in the competitive pharmaceutical market.
Being a global, commercial-stage biopharmaceutical company, Ascentage Pharma focuses on discovering, developing, and commercializing novel therapies to address unmet medical needs in oncology. The inclusion of its drugs in the NRDL is a pivotal moment for the company, reflecting its commitment to providing innovative solutions for cancer treatment.
Background
Ascentage Pharma Group International, identified by CIK 0002023311 and trading under the ticker AAPG on the Nasdaq, operates within the Pharmaceutical Preparations sector (SIC: 2834). The company has been actively filing reports, with the latest being a 6-K on November 16, 2026. This filing includes important updates about its product offerings and strategic initiatives.
What the Filing Says
The recent filing highlights two key announcements made by Ascentage Pharma on November 16, 2026. Firstly, Lisaftoclax has been included in the NRDL for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Secondly, Olverembatinib has successfully renewed its NRDL coverage for specific patient groups. The filing states, "With these developments, all approved indications for both of Ascentage Pharma’s novel drugs are now covered by the NRDL." This update will officially take effect on January 1, 2027.
Impact
This inclusion in the NRDL is expected to significantly enhance treatment accessibility for patients in China. It will allow more patients to receive timely and affordable access to these innovative therapies. For Ascentage Pharma, this move solidifies its commercialization strategy and supports its ongoing innovation efforts. The pharmaceutical industry in China stands to benefit as well, as this development reinforces the value of domestically developed drugs and encourages further investment in original innovation.
What's Next
The filing does not specify what happens next, but the successful inclusion of these drugs in the NRDL sets a strong foundation for Ascentage Pharma's future endeavors in the market.
Read Next
Cadiz Inc. reports Q3 results, shows $7.07 million loss
IGI CEO to Present at Southwest IDEAS Investor Conference
Unicycive Therapeutics announces third-quarter results
FF EAI Robotics Ecosystem reports Q3 results amid challenges
Wetouch Technology Inc. Reports Q3 2026 Financial Results
AirJoule Technologies Reports Strong Q3 Results and Growth







